Saturday, July 11, 2026
🇺🇸 FDA

Drug profile · INN

sars-cov-

sars-cov- is an FDA-listed pharmaceutical active ingredient.

NMPA: clinical trials
Patents linked 15
Pipeline programs 50
News articles 0
Drug details — sars-cov-
Class
—
Route
—
Patents
15
Programs
50
Data quality
0.70
← All drugs Related patents Pipeline programs Drug news hub Event calendar

Quick answer

sars-cov- is an FDA-listed pharmaceutical active ingredient.

Key facts

INN sars-cov-

Approval history

Authority Status Date
NMPA clinical trials —

Pipeline programs

Browse pipeline
  1. ARCT-154 Self-Amplifying RNA SARS-CoV-2 Vaccine Phase 3 · Arcturus Therapeutics · COVID-19 Vaccines
  2. Azvudine Phase 3 · Henlius USA · SARS-CoV-2 Infection
  3. Bemnifosbuvir (BEM) Phase 3 · Atea Pharmaceuticals · Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV 2
  4. C4671026 Phase 3 · First Biotech (Australia) · SARS-CoV-2 Infection
  5. Evolocumab Phase 3 · COLLEGIUM PHARMACEUTICAL · Sars-CoV-2 Infection
  6. METFORMIN for PASC: post-acute sequelae of SARS-CoV-2 infection Phase 3 · Disc Medicine · PASC: post-acute sequelae of SARS-CoV-2 infection
  7. METFORMIN, COLCHICINE Phase 3 · Disc Medicine · PASC: post-acute sequelae of SARS-CoV-2 infection
  8. MK-4482-023 Phase 3 · MSD Merck Sharp · SARS-CoV-2 (COVID-19) infection

Related patents

Browse patents

  1. WO 2026047603

    COMPOSITIONS IMMUNOGÈNES CONTRE SARS-COV-2

    Expires Wed Feb 28 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 20260035439

    Anti-Sars-COV-2 Antibodies and Uses Thereof

    Expires Wed Jan 31 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 12331078

    Stabilizing mutants of prefusion SARS-CoV-2 (COVID-19) spike protein and improved yeast surface display engineering platform for the same

    Expires Mon Jun 12 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 12251440

    Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments

    Expires Mon Mar 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 11999777

    Methods for treating or preventing SARS-CoV-2 infections and COVID-19 with anti-SARS-CoV-2 spike glycoprotein antibodies

    Expires Mon May 30 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 11993644

    Antigen binding molecules targeting SARS-CoV-2

    Expires Mon May 23 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. WO 2024068265

    PARTICULES DE TYPE VIRUS PRÉSENTANT DES ANTIGÈNES DU SARS-COV-2 UTILISÉES EN TANT QUE VACCINS DE RAPPEL ET LEURS UTILISATIONS

    Expires Wed Mar 30 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 11739137

    Single domain antibodies to SARS-CoV-2 nucleocapsid protein

    Expires Mon Aug 24 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 11732030

    Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments

    Expires Mon Aug 17 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. WO 2022229817

    VACCINS COMPRENANT DES PARTICULES PSEUDO-VIRALES PRÉSENTANT DES ANTIGÈNES DU SARS-COV-2 ET LEURS MÉTHODES D'UTILISATION

    Expires Wed Oct 29 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 11479599

    Antibodies against SARS-CoV-2 and methods of using the same

    Expires Mon Oct 20 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 11168128

    Antibodies against SARS-CoV-2 and methods of using the same

    Expires Mon Nov 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 10975139

    Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments

    Expires Mon Apr 08 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 10954289

    Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments

    Expires Mon Mar 18 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 10787501

    Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments

    Expires Mon Sep 24 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is sars-cov-?

sars-cov- is an FDA-listed pharmaceutical active ingredient.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.